{
    "nct_id": "NCT04913285",
    "official_title": "A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF And/or NRAS Mutation-positive Solid Tumors.",
    "inclusion_criteria": "* Provide written informed consent prior to initiation of any study-specific procedures.\n* Metastatic or advanced stage solid tumor\n* Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.\n* Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.\n* ECOG performance status 0-1\n* Adequate organ function, as measured by laboratory values (criteria listed in protocol).\n* Able to swallow, retain, and absorb oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)\n* In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.\n* GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.\n* Active, uncontrolled bacterial, fungal, or viral infection.\n* Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded\n* Women who are lactating or breastfeeding, or pregnant.\n* Participants with any other active treated malignancy within 3 years prior to enrollment\n\nComplete inclusion and exclusion criteria are listed in the clinical study protocol.",
    "miscellaneous_criteria": ""
}